Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma

The impact of bridging therapy (BT) administered between leukapheresis and chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is unclear. We evaluated the influence of BT (systemic therapy [ST], radiation therapy [RT], or combined-modality therapy [CMT]) on outcomes of 1...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood advances 2020-07, Vol.4 (13), p.2871-2883
Hauptverfasser:	Pinnix, Chelsea C., Gunther, Jillian R., Dabaja, Bouthaina S., Strati, Paolo, Fang, Penny, Hawkins, Misha C., Adkins, Sherry, Westin, Jason, Ahmed, Sairah, Fayad, Luis, Lee, Hun Ju, Nair, Ranjit, Steiner, Raphael E., Iyer, Swaminathan P., Rodriguez, M. Alma, Wang, Michael, Flowers, Christopher, Neelapu, Sattva S., Nastoupil, Loretta J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens, CD19 - therapeutic use Biological Products Clinical Trials and Observations Humans Immunotherapy, Adoptive Lymphoma, Large B-Cell, Diffuse - drug therapy Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!